Publications by authors named "Anne Louise Aabom"

2 Publications

  • Page 1 of 1

A specific assay for quantification of human C4c by use of an anti-C4c monoclonal antibody.

J Immunol Methods 2014 Mar 25;405:87-96. Epub 2014 Jan 25.

Department of Cancer & Inflammation Research, Institute of Molecular Medicine, Faculty of Health Science, University of Southern Denmark, Odense, Denmark. Electronic address:

The increasing evidence of the implication of the complement system in the pathogenesis of several diseases has emphasized the need for the development of specific and valid assays, optimized for quantitative detection of complement activation in vivo. In the present study, we have developed a mouse monoclonal antibody (mAb) that is able to detect fluid phase C4c without interference from other products generated from the complement component C4. The C4c specific mAb was tested in different enzyme-linked immunosorbent assay (ELISA) combinations with various types of in vitro activated sera and samples from factor I deficient patients. The specificity of the mAb was further evaluated by immunoprecipitation techniques and by analysis of eluted fragments of C4 after immunoaffinity chromatography. The anti-C4c mAb was confirmed to be C4c specific, as it showed no cross-reactivity with native (un-cleaved) C4, C4b, iC4b, or C4d. Also, no reaction was observed with C4 fragments in factor I deficient plasma or serum samples. We established and validated a sandwich ELISA based on this C4c specific antibody. The normal range of C4c in EDTA/futhan plasma collected from 100 Danish blood donors was measured, with a mean of 0.85mg/L and a range of 0.19-2.21mg/L. We believe that the C4c specific antibody and the ELISA might be important tools in the future assessment of in vivo activation in situations where the classical or the lectin complement pathways are involved in the pathogenesis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2014.01.011DOI Listing
March 2014

[Several new treatment possibilities of hereditary angio-oedema].

Ugeskr Laeger 2012 Aug;174(34):1894-8

Hudafdeling I, Odense Universitetshospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.

Hereditary angio-oedema (HAE) is a rare genetic disease caused by deficiency of complement C1 inhibitor. It is characterised by recurrent episodes of subcutaneous or submucosal oedema typically involving the extremities, bowel, face or larynx. Within the latest years it has become evident that the active mediator of HAE attacks is an increased level of bradykinin and various new treatment modalities have been developed. The aim of this paper is to give an update from the Danish HAE Comprehensive Care Centre on current treatment possibilities and address some of the challenges when diagnosing HAE.
View Article and Find Full Text PDF

Download full-text PDF

Source
August 2012
-->